| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Malcolm Peet, David F Horrobi. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of psychiatric research. vol 36. issue 1. 2002-02-27. PMID:11755456. |
115 patients with dsm-iv-defined schizophrenia were studied, 31 on clozapine, 48 on new atypical drugs and 36 on typical antipsychotics. |
2002-02-27 |
2023-08-12 |
Not clear |
| A Mechri, J Micallef, O Blin, M Saoud, J Daléry, L Gah. [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses]. Therapie. vol 56. issue 5. 2002-02-27. PMID:11806303. |
in healthy subjects, a sub-anaesthetic single dose of lorazepam, typical neuroleptics, such as haloperidol, and atypical neuroleptics, such as clozapine and olanzapine, failed to block ketamine-induced positive and negative symptoms resembling schizophrenia. |
2002-02-27 |
2023-08-12 |
human |
| M Bourin, B Guitton, E Dailly, P Hery, P Jollie. A follow-up study of a population of schizophrenic patients treated with clozapine. Progress in neuro-psychopharmacology & biological psychiatry. vol 25. issue 8. 2002-02-26. PMID:11642649. |
its efficacy for the treatment of the symptoms of schizophrenia is known, but the use of clozapine is limited to treatment-resistant schizophrenic patients as it induces agranulocytosis with a higher incidence than that of other neuroleptic drugs. |
2002-02-26 |
2023-08-12 |
human |
| K N R Chengappa, J Vasile, J Levine, R Ulrich, R Baker, A Gopalani, N Schoole. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia research. vol 53. issue 1-2. 2002-02-22. PMID:11728832. |
over a three year period, 137 subjects with schizophrenia or schizoaffective disorder received clozapine, of whom nearly 50% (n=69) experienced seclusion or restraint. |
2002-02-22 |
2023-08-12 |
human |
| A Wirz-Justice, H J Haug, C Cajoche. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophrenia bulletin. vol 27. issue 3. 2002-02-07. PMID:11596850. |
the circadian rest-activity cycle of schizophrenia patients stabilized for more than a year on monotherapy with a "classical" neuroleptic (haloperidol, flupentixol) or with the atypical neuroleptic clozapine was documented by continuous activity monitoring for 3-7 weeks. |
2002-02-07 |
2023-08-12 |
Not clear |
| B A Johansson, H Jarbin, J Lundgre. [Difficulties in the treatment of psychosis in young patients with epilepsy]. Lakartidningen. vol 98. issue 49. 2002-02-01. PMID:11783054. |
we will argue for considering clozapine early in treatment if other antipsychotics have failed based on two cases; these patients both developed epilepsy in early childhood and schizophrenia in mid adolescence. |
2002-02-01 |
2023-08-12 |
Not clear |
| S G Potkin, K Fleming, Y Jin, B Gulasekara. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of clinical psychopharmacology. vol 21. issue 5. 2002-01-24. PMID:11593072. |
neurocognition and clinical symptomatology were evaluated in 27 patients with schizophrenia during a double-blind, placebo-controlled, cross-over study involving clozapine, an atypical antipsychotic agent, and haloperidol, a conventional neuroleptic. |
2002-01-24 |
2023-08-12 |
Not clear |
| D C Goff, L Leahy, I Berman, T Posever, L Herz, A C Leon, S A Johnson, G Lync. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 5. 2002-01-24. PMID:11593073. |
a placebo-controlled pilot study of the ampakine cx516 added to clozapine in schizophrenia. |
2002-01-24 |
2023-08-12 |
Not clear |
| D A Revick. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Current opinion in investigational drugs (London, England : 2000). vol 2. issue 1. 2002-01-22. PMID:11527002. |
the research evidence suggests that clozapine is a cost-effective treatment for neuroleptic refractory schizophrenia. |
2002-01-22 |
2023-08-12 |
Not clear |
| H Silve. Fluvoxamine as an adjunctive agent in schizophrenia. CNS drug reviews. vol 7. issue 3. 2002-01-14. PMID:11607044. |
the balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotics and suggests that it may also do so in some patients treated with clozapine. |
2002-01-14 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
cyp1a2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. |
2002-01-09 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics. |
2002-01-09 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
patients with schizophrenia or schizoaffective disorder were prospectively monitored during clozapine treatment (n = 18). |
2002-01-09 |
2023-08-12 |
Not clear |
| J P Lindenmayer, J Volavka, J Lieberman, B Sheitman, L Citrome, M Chakos, P Czobor, B Parker, A Iskande. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476131. |
this article presents an open-label, prospective, 14-week trial with olanzapine in patients with schizophrenia and schizoaffective disorder selected for unambiguous resistance to either clozapine or risperidone and to typical antipsychotics. |
2002-01-09 |
2023-08-12 |
Not clear |
| J H Lee, J I Woo, H Y Meltze. Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry research. vol 103. issue 2-3. 2002-01-03. PMID:11549404. |
effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. |
2002-01-03 |
2023-08-12 |
human |
| M J Sernyak, R Rosenheck, R Desai, M Stolar, G Rippe. Impact of clozapine prescription on inpatient resource utilization. The Journal of nervous and mental disease. vol 189. issue 11. 2002-01-02. PMID:11758660. |
all patients who had clozapine initiated during an inpatient hospitalization within the va for schizophrenia over a 4-year period (n = 1415) were matched with a comparison group (n = 2,830) on key service utilization variables and other possible confounding demographic and clinical variables using propensity scoring-an accepted statistical method, although still relatively little used in psychiatry. |
2002-01-02 |
2023-08-12 |
Not clear |
| B C Lund, P J Perry, J M Brooks, S Arnd. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of general psychiatry. vol 58. issue 12. 2001-12-28. PMID:11735847. |
clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. |
2001-12-28 |
2023-08-12 |
Not clear |
| B C Lund, P J Perry, J M Brooks, S Arnd. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of general psychiatry. vol 58. issue 12. 2001-12-28. PMID:11735847. |
numerous case reports have linked clozapine to the development of diabetes mellitus and hyperlipidemia in patients with schizophrenia. |
2001-12-28 |
2023-08-12 |
Not clear |
| M Mueck-Weymann, J Acker, M W Agelin. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. Psychopharmacology. vol 157. issue 4. 2001-12-19. PMID:11605095. |
autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. |
2001-12-19 |
2023-08-12 |
Not clear |
| L Citrome, J Volavka, P Czobor, B Sheitman, J P Lindenmayer, J McEvoy, T B Cooper, M Chakos, J A Lieberma. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 52. issue 11. 2001-12-14. PMID:11684748. |
effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. |
2001-12-14 |
2023-08-12 |
Not clear |